ADVANCED BIODESIGN (ABD) Revenue and Competitors

Saint-Priest,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ADVANCED BIODESIGN (ABD)'s estimated annual revenue is currently $4M per year.(i)
  • ADVANCED BIODESIGN (ABD)'s estimated revenue per employee is $155,000

Employee Data

  • ADVANCED BIODESIGN (ABD) has 26 Employees.(i)
  • ADVANCED BIODESIGN (ABD) grew their employee count by 13% last year.

ADVANCED BIODESIGN (ABD)'s People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is ADVANCED BIODESIGN (ABD)?

Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility to the technology transfer. Their services include: Monoclonal Antibody development Polyclonal Antibody Development Antibody Production (in vitro, in vivo) Antibody Characterization (WB, Isotyping...) Antibody Purification Antibody Fragmentation Antibody Labeling Assay Developments Functionalized Supports Depending on your project, and other needs, more specific services can be designed.

keywords:N/A

N/A

Total Funding

26

Number of Employees

$4M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ADVANCED BIODESIGN (ABD) News

2022-04-06 - Global, regional, and national burden of colorectal cancer and ...

Rajesh Sharma, Mohsen Abbasi-Kangevari, Rami Abd-Rabu, Hassan Abidi, ... School of Advanced Technologies in Medicine (S Ahmadi PhD),...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A2613%N/A
#2
$6.1M317%N/A
#3
N/A8121%N/A
#4
N/A9114%N/A
#5
$88M24420%N/A